Cenix, Metanomics Partner to Develop Metabolomic Biomarkers
News Sep 05, 2014
As the agreement’s first work assignment, Metanomics Health has commissioned Cenix to undertake a target validation project for an undisclosed disease indication. Under the jointly developed work plan, Cenix will leverage its longstanding industry-leading expertise in high content screening, utilizing the Definiens XD image analysis platform, for comprehensive functional characterization of target genes designated by Metanomics Health.
“We foresee very strong synergies between our own capabilities and the exciting approach taken by Metanomics Health towards biomarker discovery and validation,” said Dr. Christophe Echeverri, CEO/CSO of Cenix. “We appreciate and value the trust of our colleagues at Metanomics Health and look forward to advancing their programs”.
Financial terms were not disclosed.
Measuring hand grip can help identify youths who could benefit from lifestyle changes, says new research. While other studies have shown that muscle weakness as measured by grip strength is a predictor of unhealthy outcomes - including cardiovascular and metabolic diseases - this is the first to do so for adolescent health over time.READ MORE
Virtually all functions in our bodies require precise interactions between radically different types of molecules. A new study aims to understand how RNA molecules pair with intended protein partners. Researchers hope that they eventually will be able to predict and manipulate these partnerships that have been carved through millions of years of evolution.READ MORE
Researchers have identified a protein at the head of a pathway that leads to neuronal death. They found that the enzyme HDAC1, normally in the nucleus of cells, is also present in the axons of some neurons. When a degenerative signal is activated, HDAC1 modifies a component of a molecular motor, which then drives a signaling agent down the axon to the neuron’s cell body, killing it.READ MORE